SCHEMBL25324576

SCHEMBL25324576

C[C@@H]1CCC[C@H](c2ccccc2)N1C(=O)C(N)=O

nearest known ligand 0.58

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ PRMT5 O14744 2/20 0.58
▸ WDR77 Q9BQA1 2/20 0.58
▸ ALDH1A1 P00352 1/20 0.49
▸ GLA P06280 1/20 0.49
▸ HPGD P15428 1/20 0.49
▸ RIPK1 Q13546 3/20 0.43
▸ CHRNB2 P17787 1/20 0.41
▸ CHRNB4 P30926 1/20 0.41
▸ CHRNA3 P32297 1/20 0.41
▸ CHRNA7 P36544 1/20 0.41
▸ CHRNA4 P43681 1/20 0.41
▸ SIGMAR1 Q99720 1/20 0.41
▸ KMT2A Q03164 2/20 0.41
▸ SMN1; SMN2 Q16637 1/20 0.40
▸ MEN1 O00255 1/20 0.40
▸ L3MBTL1 Q9Y468 1/20 0.39
▸ ACHE P22303 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25324578 1.00 PRMT5 (0.58) PRMT5WDR77ALDH1A1GLAHPGD
Ammonia Solution, Strong SCHEMBL25323733 0.99 PRMT5 (0.57) PRMT5WDR77ALDH1A1GLAHPGD
Ammonia Solution, Strong SCHEMBL25323728 0.99 PRMT5 (0.57) PRMT5WDR77ALDH1A1GLAHPGD
SCHEMBL24367528 0.88 PRMT5 (0.57) PRMT5WDR77ALDH1A1GLAHPGD
SCHEMBL29477756 0.84 PRMT5 (0.54) PRMT5WDR77ALDH1A1GLAHPGD
SCHEMBL24366650 0.83 PRMT5 (0.56) PRMT5WDR77ALDH1A1GLAHPGD
SCHEMBL24366978 0.83 PRMT5 (0.56) PRMT5WDR77ALDH1A1GLAHPGD
SCHEMBL5516152 0.79 PRMT5 (0.52) PRMT5WDR77ALDH1A1GLAHPGD
SCHEMBL25321489 0.79 RIPK1 (0.43) PRMT5WDR77ALDH1A1RIPK1CHRNB2
SCHEMBL25321486 0.79 RIPK1 (0.43) PRMT5WDR77ALDH1A1RIPK1CHRNB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250163048-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. 2025-05-22 — — US disclosed
EP-4469455-A1 COMPOUNDS AND METHODS OF USE Tango Therapeutics, Inc. (US) 2024-12-04 — — EP disclosed
WO-2023146990-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. (US) 2023-08-03 — — WO disclosed
WO-2023146990-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. (US) 2023-08-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250163048-A1 COMPOUNDS AND METHODS OF USE RB1, CYP1B1, REN PRMT5 562/4885WDR77 1925/4885ALDH1A1 79/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback